Every 10-Q that Medicus Pharma Ltd. (MDCX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.
Medicus Pharma Ltd. reported a larger loss and higher spending for the quarter and six months ended June 30, 2026, while significantly increasing its cash through new debt and equity financings. The company remains a clinical-stage biotech with no product revenue and focuses on its SkinJect microneedle cancer patch and Teverelix programs.
Total assets were $27.1 million, including cash and cash equivalents of $15.2 million and restricted cash of $10.0 million, against total liabilities of $28.8 million, resulting in a shareholders’ deficit of $1.7 million. The six‑month net loss widened to $20.7 million from $11.3 million a year earlier, driven by higher general and administrative expenses of $12.5 million and research and development expenses of $7.6 million, including increased Teverelix trial activity and stock‑based compensation.
Operating cash use was $16.0 million over six months, funded by $32.4 million of financing inflows: $22.0 million in secured promissory notes, $12.4 million from an at‑the‑market program and $4.1 million from a standby equity purchase agreement, partly offset by debenture repayment. Management discloses substantial doubt about the company’s ability to continue as a going concern without further capital and notes a Nasdaq minimum bid‑price deficiency.
Medicus Pharma Ltd. reports first-quarter 2026 results, with a net loss of $9.0M and no revenue as it advances its drug pipeline. Operating expenses rose sharply, driven by higher general and administrative spending and increased research and development, including work on Teverelix and SkinJect.
Cash and cash equivalents were $6.4M as of March 31, 2026, after using $9.0M in operating cash during the quarter and raising equity through a standby equity purchase agreement and at-the-market sales. Management discloses substantial doubt about the company’s ability to continue as a going concern.
The company expanded its at-the-market program and continued to rely on Yorkville-financed debentures and equity facilities, while also reporting positive Phase 2 data for its SkinJect microneedle therapy and FDA clearance to begin a Phase 2b study of Teverelix in advanced prostate cancer.
Medicus Pharma Ltd. (MDCX) is a clinical-stage life sciences company focused on advancing a dissolvable doxorubicin microneedle array program (SkinJect) and opportunistic biotech acquisitions. The company reported $9,669,546 in cash and cash equivalents at June 30, 2025, up from $4,164,323 at year-end 2024, driven by equity offerings and warrant exercises.
Operating losses widened: a six-month net loss of $11,278,492 in 2025 versus $5,340,217 in 2024, producing an accumulated deficit of $40,182,395. Cash used in operations was $9,409,825 for the six months. The company closed a $4.17M Regulation A offering and a $7.01M June 2025 public offering, issued debentures for $4.5M (principal $5.0M) and entered a SEPA commitment for up to $15M. The company also agreed to acquire Antev Limited for consideration shares and contingent payments up to $65M. Management discloses substantial doubt about going concern and identified material weaknesses in internal controls.